Overview

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-06-28

Target enrollment:

Participant gender:

Summary

This study now plans to explore the efficacy and safety of hetrombopag in chemotherapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced platelets.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.